Abiopharma

🔍 GALANTE EDWARD G (Director)

Company: Celanese Corp (CE)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 1,930 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 27,983.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5 shares of Phantom Stock (Derivative)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,814.82 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Annual grant of fully vested restricted stock units pursuant to the Amended and Restated Company's 2018 Global Incentive Plan. The restricted stock units were granted to compensate the reporting person for his prior service as Chair of the Board.
• F2: Each share of phantom stock represents the right to receive one share of Common Stock.
• F3: The reported phantom stock represents dividend equivalents on compensation deferred under the Company's 2008 Deferred Compensation Plan (the "Plan"). The shares of phantom stock become payable in shares of Common Stock, as provided in the Plan, following the termination of the reporting person's service as a director of the Company.